Metastatic Triple-Negative Breast Cancer

Uses

Benefits

Risks & contraindications

Highlighted claims

• In IMpassion130, atezolizumab plus nab-paclitaxel improved median progression-free survival in untreated PD-L1-positive metastatic triple-negative breast cancer from 5.0 to 7.5 months. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
• Patients with metastatic triple-negative breast cancer generally have poor prognosis, with median overall survival of about one year. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
• Immune checkpoint inhibitor plus chemotherapy combinations have become standard first-line treatment for PD-L1-positive metastatic triple-negative breast cancer. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
• Despite benefit from atezolizumab plus nab-paclitaxel, about 20% of treated patients in IMpassion130 progressed within three months. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
• Angiogenesis was associated with reduced progression-free survival in this disease context. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)